These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20569146)

  • 1. The exploitation of "Exploitation" in the tenofovir prep trial in Cameroon: Lessons learned from media coverage of an HIV prevention trial.
    Mack N; Robinson ET; MacQueen KM; Moffett J; Johnson LM
    J Empir Res Hum Res Ethics; 2010 Jun; 5(2):3-19. PubMed ID: 20569146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI; Okoromah CA
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007189. PubMed ID: 19160329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tenofovir pre-exposure prophylaxis trial in Thailand: researchers should show more openness in their engagement with the community.
    Chua A; Ford N; Wilson D; Cawthorne P
    PLoS Med; 2005 Oct; 2(10):e346. PubMed ID: 16231979
    [No Abstract]   [Full Text] [Related]  

  • 4. Women testing tenofovir for HIV prevention.
    AIDS Patient Care STDS; 2005 Feb; 19(2):128. PubMed ID: 15747428
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J; Dufrene SL; Okulicz JF
    Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
    Landman R; Koulla-Shiro S; Sow PS; Ngolle M; Diallo MB; Guèye NF; Le Moing V; Eymard-Duvernay S; Benalycherif A; Charpentier C; Peytavin G; Delaporte E; Girard PM;
    Antivir Ther; 2014; 19(1):51-9. PubMed ID: 23970206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of antiretroviral for HIV prevention on hold.
    Ahmad K
    Lancet Infect Dis; 2004 Oct; 4(10):597. PubMed ID: 15470760
    [No Abstract]   [Full Text] [Related]  

  • 9. Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial.
    Karim QA; Kharsany AB; Naidoo K; Yende N; Gengiah T; Omar Z; Arulappan N; Mlisana KP; Luthuli LR; Karim SS
    Contemp Clin Trials; 2011 May; 32(3):333-8. PubMed ID: 21278001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI; Uthman OA; Okoromah CA
    Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethics and HIV prevention research: An analysis of the early tenofovir PrEP trial in Nigeria.
    Peterson K; Folayan MO
    Bioethics; 2019 Jan; 33(1):35-42. PubMed ID: 30198594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AIDS drug trial turned away; protests by prostitutes in Cambodia ended Tenofovir testing.
    Cha AE
    Washington Post; 2006 May; ():A10, A14. PubMed ID: 16856292
    [No Abstract]   [Full Text] [Related]  

  • 13. The trials of tenofovir trials.
    Lancet; 2005 Mar 26-Apr 1; 365(9465):1111. PubMed ID: 15799093
    [No Abstract]   [Full Text] [Related]  

  • 14. Pregnancy prevention practices among women with multiple partners in an HIV prevention trial.
    Macqueen KM; Johnson L; Alleman P; Akumatey B; Lawoyin T; Nyiama T
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):32-8. PubMed ID: 17667340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIDS clinical trials. More woes for novel HIV prevention approach.
    Cohen J
    Science; 2005 Mar; 307(5716):1708. PubMed ID: 15774734
    [No Abstract]   [Full Text] [Related]  

  • 16. Tenofovir gel--the new HIV prevention 'banker'?
    Bateman C
    S Afr Med J; 2007 Jul; 97(7):496, 498. PubMed ID: 17805450
    [No Abstract]   [Full Text] [Related]  

  • 17. Tenofovir: a pill to prevent HIV?
    Bonn D
    Lancet Infect Dis; 2005 Feb; 5(2):78. PubMed ID: 15702509
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA treads carefully with PrEP.
    Holmes D
    Lancet Infect Dis; 2012 Jul; 12(7):515-6. PubMed ID: 22930826
    [No Abstract]   [Full Text] [Related]  

  • 19. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E; Cohan D
    AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.